RU-58841 is a topical non-steroidal antiandrogen originally developed by Roussel-Uclaf and studied for scalp application to locally block DHT and reduce androgenic hair loss, without the systemic hormonal effects of oral antiandrogens. It was never brought to market and remains a research/compounding-only compound with limited modern safety data.
The human safety trial exists but was never published
A Phase I human safety study of RU58841 (30 men with male-pattern baldness, 5% solution applied topically twice daily for 4 weeks, run by Prostrakan in the early 2000s) was conducted — but its results were never published. This means the compound has genuinely been tested in humans, but there's no accessible peer-reviewed record of what that trial found — a meaningfully different (and worse) situation than "no human trial exists at all," since it suggests real data exists that simply isn't public.
Benefits
RU58841 is a topical, non-steroidal antiandrogen, studied in animal models for hair regrowth. Balding-scalp-graft study (human scalp grafts on testosterone-conditioned nude mice, not living human subjects): RU58841-treated grafts showed significantly higher linear hair growth than controls. Brouwer et al., Br J Dermatol, 1997 With the human trial unpublished, dosing, efficacy, and safety in actual humans remain effectively untested from a public-evidence standpoint.
Is RU-58841 FDA-approved?+
No. It was studied decades ago but never approved or commercialized, and current supply comes from research/compounding sources rather than a regulated pharmaceutical.
How is RU-58841 different from oral antiandrogens like finasteride?+
It is designed to act locally on the scalp rather than systemically, with the aim of avoiding the body-wide hormonal side effects associated with oral antiandrogens.
Is there recent clinical data on RU-58841?+
Human data is largely limited to older, smaller studies from its original development; it has not been through modern large-scale trials.
So is it a safer alternative to finasteride?+
Potentially, mechanistically — since it works locally at the scalp rather than systemically, avoiding finasteride's body-wide DHT reduction. But the honest caveat is RU-58841 never made it through late-stage human trials, and development was discontinued. Very little real human data actually confirms that theoretical safety advantage.
Looking for something specific, or placing a wholesale order? Send us a DM or email.